# EDGAR Filing Document

**Accession Number:** 0001472012
**File Stem:** 0001104659-23-033088
**Filing Date:** 2023-3
**Character Count:** 18868
**Document Hash:** cce3994af74181f16036eaa49e68f641
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-033088.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0001104659-23-033088

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 7

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**EFFECTIVENESS DATE**: 20230316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immunome Inc.
- **CENTRAL INDEX KEY:** 0001472012
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 770694340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270598
- **FILM NUMBER:** 23737249

**BUSINESS ADDRESS:**
- **STREET 1:** 665 STOCKTON DRIVE
- **STREET 2:** SUITE 300
- **CITY:** EXTON
- **STATE:** PA
- **ZIP:** 19341
- **BUSINESS PHONE:** 610-321-3700

**MAIL ADDRESS:**
- **STREET 1:** 665 STOCKTON DRIVE
- **STREET 2:** SUITE 300
- **CITY:** EXTON
- **STATE:** PA
- **ZIP:** 19341

**As filed with the Securities and Exchange Commission on March 16, 2023**

**Registration No. 333-** 

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER<br> THE SECURITIES ACT OF 1933***

**IMMUNOME, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| **Delaware**<br> (State or Other Jurisdiction of<br> Incorporation or Organization) | **77-0694340**<br> (I.R.S. Employer Identification<br> Number) |

---

**665 Stockton Drive, Suite 300**

**Exton, PA 19341**

**(610) 321-3700**

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

**Immunome, Inc. 2020 Equity Incentive Plan**

**Immunome, Inc. 2020 Employee Stock Purchase Plan**<br> (Full title of the plans)

**Purnanand D. Sarma**<br> **President and Chief Executive Officer**<br> **Immunome, Inc.**<br> **665 Stockton Drive, Suite 300**<br> **Exton, PA 19341<br> (610) 321-3700**<br> (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)<br>*Copy to:*<br>**Daniel A. Bagliebter, Esq.**<br> **Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.**<br> **919 Third Avenue New York, NY 10022** <br> **(212) 935-3000**<br>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
|  |  | Emerging growth company | ⌧ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

This registration statement registers an aggregate of 1,211,958 additional shares of common stock, par value $0.0001 per share ("common stock"), of Immunome, Inc. (the "Registrant") reserved under (i) the Registrant's 2020 Equity Incentive Plan (the "2020 Plan"), representing an increase of (x) 484,414 shares reserved under the 2020 Plan effective January 1, 2022 and (y) 485,153 shares reserved under the 2020 Plan effective January 1, 2023, by operation of the 2020 Plan's "evergreen" provision, and (ii) the Registrant's 2020 Employee Stock Purchase Plan (the "2020 ESPP"), representing an increase of (x) 121,103 shares reserved under the 2020 ESPP effective January 1, 2022 and (y) 121,288 shares reserved under the 2020 ESPP effective January 1, 2023 by operation of the 2020 ESPP's "evergreen" provision. This registration statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 (File No. 333-254731) relating to an employee benefit plan is effective. The information contained in the Registrant's registration statement on [Form S-8 filed with the Securities and Exchange Commission on March 25, 2021 (File No. 333-254731)](http://www.sec.gov/Archives/edgar/data/1472012/000110465921041594/tm2110963d1_s8.htm) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8.** **Exhibits.**

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 3.1 | [Amended and Restated Certificate of Incorporation of Immunome, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K dated October 6, 2020 (SEC File No. 001-39580)).](http://www.sec.gov/Archives/edgar/data/1472012/000110465920112632/tm2032458d1_ex3-1.htm) |
| 3.2 | [Amended and Restated Bylaws of Immunome, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K dated October 6, 2020 (SEC File No. 001-39580)).](http://www.sec.gov/Archives/edgar/data/1472012/000110465920112632/tm2032458d1_ex3-2.htm) |
| 4.1 | [Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to our Registration Statement on Form S-1/A filed on September 24, 2020 (SEC File No. 333-248687)).](http://www.sec.gov/Archives/edgar/data/1472012/000110465920108076/tm2025599d7_ex4-2.htm) |
| 5.1\* | [Legal opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.](tm239583d2_ex5-1.htm) |
| 23.1\* | [Consent of Deloitte & Touche LLP, independent registered public accounting firm for Registrant.](tm239583d2_ex23-1.htm) |
| 23.2\* | [Consent of Ernst & Young LLP, independent registered public accounting firm for Registrant.](tm239583d2_ex23-2.htm) |
| 23.3\* | [Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).](tm239583d2_ex5-1.htm) |
| 24.1\* | [Powers of Attorney (set forth on the signature page to this Registration Statement).](#a_001) |
| 99.1+ | [2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to Amendment No. 1 to our Registration Statement on Form S-1/A filed on September 24, 2020 (SEC File No. 333-248687)).](http://www.sec.gov/Archives/edgar/data/1472012/000110465920108076/tm2025599d7_ex10-6.htm) |
| 99.2+ | [2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 to Amendment No. 1 to our Registration Statement on Form S-1/A filed on September 24, 2020 (SEC File No. 333-248687)).](http://www.sec.gov/Archives/edgar/data/1472012/000110465920108076/tm2025599d7_ex10-8.htm) |
| 107\* | [Filing Fee Table](tm239583d2_ex-filingfees.htm) |

---

\* Filed herewith

+ Denotes management contract or compensatory plan or arrangement.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Exton, Commonwealth of Pennsylvania, on March 16, 2023.

---

| | |
|:---|:---|
| IMMUNOME, INC. | IMMUNOME, INC. |
| By: | /s/ Purnanand D. Sarma, Ph. D |
|  | Purnanand D. Sarma, Ph. D |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below hereby designates, constitutes and appoints each of Michael Rapp and Purnanand D. Sarma, Ph.D. (with full power to each to act alone) as his true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution (the "Attorneys-in-Fact"), for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments), which amendments may make such changes in this Registration Statement as any Attorney-in-Fact deems appropriate, supplements, subsequent registration statements relating to the offering to which this Registration Statement relates, or other instruments he deems necessary or appropriate, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to each such Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as each signatory might or could do in person, and hereby ratifies and confirms all that said Attorneys-in-Fact or any of them or his or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in their respective capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| Signature | Title | Date |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Purnanand D. Sarma, Ph.D. | President, Chief Executive Officer | March 16, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purnanand D. Sarma, Ph.D. | and Director (Principal Executive Officer) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Corleen Roche | Chief Financial Officer | March 16, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corleen Roche | (Principal Financial Officer and Principal Accounting Officer) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Michael Rapp | Chairman of the Board | March 16, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Michael Rapp |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Richard Baron | Director | March 16, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Richard Baron |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ John LaMattina, Ph.D. | Director | March 16, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John LaMattina, Ph.D. |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Michael Lefenfeld | Director | March 16, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Michael Lefenfeld |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Franklin G. Prendergast, M.D., Ph.D. | Director | March 16, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Franklin G. Prendergast, M.D., Ph.D. |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Philip Wagenheim | Director | March 16, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Philip Wagenheim |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](tm239583d2_ex5-1img001.jpg) | <br> 919 Third Avenue<br> New York, NY 10022<br> 212 935 3000<br> mintz.com<br>|

---

March 16, 2023

Immunome, Inc.

665 Stockton Drive, Suite 300

Exton, Pennsylvania 19341

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as legal counsel to Immunome, Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing with the Securities and Exchange Commission (the "Commission") of a Registration Statement on Form S-8 (the "Registration Statement"), pursuant to which the Company is registering the issuance under the Securities Act of 1933, as amended (the "Securities Act"), of an aggregate of 1,211,958 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), consisting of (i) 969,567 shares (the "2020 Plan Shares") of the Company's Common Stock, that may be issued pursuant to the Company's 2020 Equity Incentive Plan (the "2020 Plan") and (ii) 242,391 shares (the "2020 ESPP Shares", and together with the 2020 Plan Shares, the "Shares") of the Company's Common Stock that may be issued pursuant to the 2020 Employee Stock Purchase Plan (the "2020 ESPP", and together with the 2020 Plan, the "Plans"). This opinion is being rendered in connection with the filing of the Registration Statement with the Commission. All capitalized terms used herein and not otherwise defined shall have the respective meanings given to them in the Registration Statement.

In connection with this opinion, we have examined the Company's Certificate of Incorporation and Bylaws, each as currently in effect; such other records of the corporate proceedings of the Company and certificates of the Company's officers as we have deemed relevant; and the Registration Statement and the exhibits thereto.

In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such copies, and the truth and correctness of any representations and warranties contained therein. In addition, we have assumed that the Company will receive any required consideration in accordance with the terms of the Plans.

Our opinion expressed herein is limited to the General Corporation Law of the State of Delaware and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

Based upon the foregoing, we are of the opinion that the Shares, when issued and delivered in accordance with the terms of the Plans, will be validly issued, fully paid and non-assessable.

---

| | |
|:---|:---|
| **MINTZ**<br>March 16, 2023<br> Page 2 | <br>![](tm239583d2_ex5-1img002.jpg) |

---

We understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act, and we hereby consent thereto. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
| Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 28, 2022, relating to the financial statements of Immunome, Inc. appearing in the Annual Report on Form 10-K of Immunone, Inc. for the year ended December 31, 2022.

/s/ Deloitte & Touche LLP

Philadelphia, Pennsylvania

March 16, 2023

## Exhibit 23.2

**Exhibit 23.2**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of Immunome, Inc. of our report dated March 16, 2023, with respect to the financial statements of Immunome, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Philadelphia, Pennsylvania

March 16, 2023

## Ex-Filing

**Exhibit 107**

<u>Form S-8</u>

(Form Type)

<u>Immunome, Inc.</u>

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class<br> Title** | **Fee<br> Calculation<br> Rule** | **Amount<br> Registered** |  | **Proposed<br> Maximum<br> Offering<br> Price Per<br> Unit** |  | **Maximum<br> Aggregate<br> Offering<br> Price** | **Fee Rate** | **Amount of<br> Registration<br> Fee** |
| Equity | Common stock, par value $0.0001 per share | 457(c)<br> and<br> 457(h) | 1211958 | (1) | $4.325 | (2) | $5241718.35 | $0.0001102 | $577.64 |
| **Total Offering Amount** | **Total Offering Amount** |  |  |  |  |  | $5241718.35 |  | $577.64 |
| **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |  |  |  |  |  |
| **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |  |  |  |  |
| **Net Fee Due** | **Net Fee Due** |  |  |  |  |  |  |  | $577.64 |

---

(1) The number of shares of common stock,
 par value $0.0001 per share ("common stock"), of Immunome, Inc. (the "Registrant") stated above consists
 of additional shares of common stock available for issuance under the Registrant's 2020 Equity Incentive Plan (the "2020
 Plan") and 2020 Employee Stock Purchase Plan (the "2020 ESPP"), by operation of the 2020 Plan's and 2020
 ESPP's "evergreen" provisions, respectively. The maximum number of shares which may be sold upon the exercise of
 options or issuance of stock-based awards granted under the 2020 Plan and 2020 ESPP is subject to adjustment in accordance with certain
 anti-dilution and other provisions of the 2020 Plan and 2020 ESPP, respectively. Accordingly, pursuant to Rule 416 under the Securities
 Act of 1933, as amended (the "Securities Act"), this registration statement covers, in addition to the number of shares
 stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such
 anti-dilution and other provisions.

(2) Estimated solely for the purpose of calculating
 the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price
 per share and the aggregate offering price for shares reserved for future grant or issuance under the 2020 Plan and 2020 ESPP are
 based on the average of the high and the low price of Registrant's common stock as reported on The Nasdaq Capital Market as
 of a date (March 10, 2023) within five business days prior to filing this Registration Statement.